Dr Andrew Millar

Consultant Gastroenterologist

Medical Qualifications

Dr Andrew Millar qualified in 1983 and is a Fellow of the Royal Society of Medicine and the Royal College of Physicians and is also a Member of British Society of Gastroenterology. Dr Millar completed further training in the management of hepatological and gastroenterological disorders.

Medical Experience

Dr Millar has been a practising Gastroenterology Consultant since 1997 in the NHS-associated, North Middlesex University Hospital. He also see patients privately who require detailed assessment and management of irritable bowel syndrome. His Medical IBS Team includes experienced dieticians trained in modern dietary approaches.

Dr Millar is also an Honorary Senior Lecturer at the Academic Medical Unit of the Royal Free and University College London Hospitals as well as an Associate Professor of Medicine at St George's University School of Medicine, Grenada.

In practice at

BMI The King's Oak Hospital

Private

BMI The King's Oak Hospital

Specialisms

Diagnostic tests

colonoscopy

Languages spoken:

English

Articles written by Dr Andrew Millar

Chronic Hepatitis B and C

Hepatitis B and Hepatitis C are the two most common viruses known to cause long term, or chronic, infection of the liver. Chronic Hepatitis B affects 350 million people worldwide and chronic Hepatitis C, 125 million people. Hepatitis B and C can cause ‘acute’, in other words short-lived infections, or more long-term infection, ‘chronic’. There is a highly effective vaccine for Hepatitis B but NOT (yet) for Hepatitis C.

Diagnosing and Treating Irritable Bowel Syndrome - Latest Expert Advice

Many people experience Irritable Bowel Syndrome (IBS) symptoms. Often the symptoms are mild but for many the condition is a long term burden. Many patients worry that a more serious underlying problem might be the cause. This concern can often by reduced by a simple professional assessment without the need for invasive tests. Tests to exclude serious disease are important when appropriate and, in older patients, may help to reduce the risk of future colonic malignancy.